Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions

Wong, Benjamin C Y, Zhang, Lian, Ma, Jun-ling, Pan, Kai-feng, Li, Ji-you, Shen, Lin, Liu, Wei-dong, Feng, Guo-shuang, Zhang, Xiao-dong, Li, Jie, Lu, Ai-ping, Xia, Harry H X, Lam, Shiukum, You, Wei-cheng · 2012 · Gut

Abstract

Objective: Helicobacter pylori infection and overexpression of cyclo-oxygenase-2 (COX-2) are associated with gastric cancer and its precursors. To evaluate the effect of a selective COX-2 inhibitor alone and combined with H pylori eradication on the evolution of precancerous gastric lesions, a randomised, placebo-controlled trial was conducted in Linqu County, Shandong Province, China. Methods: A total of 1024 participants aged 35–64 years with H pylori infection and advanced gastric lesions were randomly assigned in a factorial design to two interventions or placebo: anti- H pylori treatment for 7 days, and a COX-2 inhibitor (celecoxib) for 24 months. The effects of the interventions were evaluated by the regression or progression of advanced gastric lesions. Results: Of the 1024 participants who received anti- H pylori treatment or placebo, 919 completed a subsequent 24-month treatment with celecoxib or placebo. The H pylori eradication rate by per-protocol analysis was 78.2%. Compared with placebo, the proportions of regression of gastric lesions significantly increased in the celecoxib treatment (52.8% vs 41.2%) and anti- H pylori treatment (59.3% vs 41.2%) group, and OR by per-protocol analysis was 1.72 (95% CI 1.07 to 2.76) for celecoxib and 2.19 (95% CI 1.32 to 3.64) for H pylori eradication. No statistically significant effect was found for H pylori eradication followed by celecoxib on the regression of advanced gastric lesions (OR 1.48, 95% CI 0.91 to 2.40). Conclusion: This population-based intervention trial revealed that celecoxib treatment or H pylori eradication alone had beneficial effects on the regression of advanced gastric lesions. No favourable effects were seen for H pylori eradication followed by celecoxib treatment. Trial registration: HARECCTR0500053 in accordance with WHO ICTRP requirements.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2011-300154

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 160

Metadata

Authors
Wong, B. C. Y., Zhang, L., Ma, J.-L., Pan, K.-F., Li, J.-Y., Shen, L., Liu, W.-D., Feng, G.-S., Zhang, X.-D., Li, J., Lu, A.-P., Xia, H. H. X., Lam, S., & You, W.-C.
Venue
Gut
Publisher
BMJ
Published
2011-09-13
Volume
61
Issue
6
Pages
812-818
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2153754546
Cited by
160
References
2
FWCI
6.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. https://app.cochat.ai/papers/10.1136/gutjnl-2011-300154
The paper
Wong, B. C. Y., Zhang, L., Ma, J.-L., Pan, K.-F., Li, J.-Y., Shen, L., Liu, W.-D., Feng, G.-S., Zhang, X.-D., Li, J., Lu, A.-P., Xia, H. H. X., Lam, S., & You, W.-C. (2012). Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. https://doi.org/10.1136/gutjnl-2011-300154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.